RxDoctor Payments Data

Ron Waksman, MD

Interventional Cardiology · Washington, DCNPI 1134170459

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $826,170 of the $914,694 with a category attached, or 90.3%. Biotronik Inc. accounts for 77.6% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $223,182 and has fallen 68.5% since, to $70,318 in 2025.

$914,694in general payments, 2019–2025

Across 410 payments — averaging $2230.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$710K
  • M.a. Med Alliance S.A.$45K
  • Boston Scientific$35K
  • Medtronic$34K
  • Philips North America LLC$27K
  • Abbott$21K
  • plus $42K from 23 others
$23,265,439in research payments, 2019–2025

Across 655 payments — averaging $35,520 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$11.1M
  • Medtronic$7.9M
  • M.a. Med Alliance S.A.$1.8M
  • Boston Scientific$535K
  • Abbott$531K
  • Biotronik Inc.$301K
  • plus $1M from 13 others

What the payments were for

  • Consulting fees$826,17090%
  • Speaking & faculty fees$36,2004%
  • Travel & lodging$42,7975%
  • Food & beverage$9,4681%
  • Entertainment$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$19,520
Medicare patients
32
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →